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ADM    PanIN     PDACSee Covering the Cover synopsis on page 1352;
See editorial on page 1376.BACKGROUND & AIMS: SIRT5 plays pleiotropic roles via post-
translational modifications, serving as a tumor suppressor, or
an oncogene, in different tumors. However, the role SIRT5 plays
in the initiation and progression of pancreatic ductal adeno-
carcinoma (PDAC) remains unknown. METHODS: Published
datasets and tissue arrays with SIRT5 staining were used to
investigate the clinical relevance of SIRT5 in PDAC. Further-
more, to define the role of SIRT5 in the carcinogenesis of PDAC,
we generated autochthonous mouse models with conditionalSirt5 knockout. Moreover, to examine the mechanistic role of
SIRT5 in PDAC carcinogenesis, SIRT5 was knocked down in
PDAC cell lines and organoids, followed by metabolomics and
proteomics studies. A novel SIRT5 activator was used for
therapeutic studies in organoids and patient-derived xeno-
grafts. RESULTS: SIRT5 expression negatively regulated tumor
cell proliferation and correlated with a favorable prognosis in
patients with PDAC. Genetic ablation of Sirt5 in PDAC mouse
models promoted acinar-to-ductal metaplasia, precursor le-
sions, and pancreatic tumorigenesis, resulting in poor survival.
Mechanistically, SIRT5 loss enhanced glutamine and gluta-
thione metabolism via acetylation-mediated activation of GOT1.
A selective SIRT5 activator, MC3138, phenocopied the effects of
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Pancreatic ductal adenocarcinoma (PDAC) cells with
activating KRAS mutations use glutamine in a
noncanonic way via the GOT2-GOT1-ME1 pathway.
SIRT5 has pleiotropic roles, serving as an oncogene and
tumor suppressor in different cancers.
NEW FINDINGS
SIRT5 is a novel tumor suppressor for pancreatic cancer
and genetically targeting SIRT5 makes PDAC tumors
more aggressive. SIRT5 negatively regulates noncanonic
glutamine metabolism via direct post-translational
November 2021 SIRT5 Inhibits Pancreatic Cancer Progression 1585SIRT5 overexpression and exhibited antitumor effects on hu-
man PDAC cells. MC3138 also diminished nucleotide pools,
sensitizing human PDAC cell lines, organoids, and patient-
derived xenografts to gemcitabine. CONCLUSIONS: Collec-
tively, we identify SIRT5 as a key tumor suppressor in PDAC,
whose loss promotes tumorigenesis through increased non-
canonic use of glutamine via GOT1, and that SIRT5 activation is
a novel therapeutic strategy to target PDAC.
Keywords: SIRT5; GOT1; Pancreatic Cancer; Glutamine Meta-
bolism; Glutathione Metabolism.
remarkable feature of pancreatic ductal adenocarci-modifications of GOT1. Activation of SIRT5 with a novel
small molecule is a potential new therapy for PDAC with
low-SIRT5 levels.
LIMITATIONS
This study was conducted in PDAC cell lines, genetically
engineered mice models, and human tissue samples
(tissue microarrays, PDAC organoids, and patient-
derived xenografts). More work needs to be done in
human patients.
IMPACT
SIRT5 activation (small-molecule SIRT5-activator
MC3138) combined with gemcitabine may lead to a
novel safe and effective therapy for patients with PDAC
with low–tumoral SIRT5 expression.
Abbreviations used in this paper: AOA, aminooxyacetate; Asp, aspartate;
CS, Pdx1-Cre, Sirt5fl/fl; GLUD1, glutamate dehydrogenase 1; GOT, gluta-
mate-oxaloacetate transaminase; GSH, glutathione; IC50, half maximal
inhibitory concentration; KCS, Pdx1-Cre, LSL-KrasG12D, Sirt5fl/fl; KPC,
KrasG12D/D, p53R172H/D, Pdx1-Cretg/D; KPCS, Pdx1-Cre, LSL-KrasG12D,
LSL-Tp53R172H, Sirt5fl/fl; ME1, malic enzyme 1; mRNA, messenger RNA;
NAD, nicotinamide adenine dinucleotide; NADPH, reduced nicotinamide
adenine dinucleotide phosphate; PanIN, pancreatic intraepithelial
neoplasia; PCR, polymerase chain reaction; PDAC, pancreatic ductal
adenocarcinoma; PDX, patient-derived xenografts; SIRT, sirtuin; UNMC,
University of Nebraska Medical Center.
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ASAnoma (PDAC) is the hypoxic, harsh, and nutrient-
deficient tumor microenvironment.1 Accordingly, PDAC cells
tend to reprogram their metabolic pathways to survive and
grow under these harsh conditions.1–3 Therefore, a deeper
understanding of the biological features and molecular regu-
lation of metabolic dependencies of PDAC is strongly expected
to provide novel targets for therapeutic interventions.
Unlike many other cells using glutamine to feed the
tricarboxylic acid cycle via glutamate dehydrogenase 1
(GLUD1), PDAC cells metabolize glutamine in a noncanonic
way.4,5Mitochondrial aspartate aminotransferase (glutamate-
oxaloacetate transaminase 2 [GOT2]) converts glutamine to
aspartate (Asp). Glutamine-derived Asp is transported to the
cytoplasm. Next, cytosolic Asp aminotransferase (GOT1)
converts glutamine-derived Asp to oxaloacetate, which is
converted tomalate by cytosolicmalate dehydrogenase. Then,
the cytoplasmicmalic enzyme 1 (ME1) catalyzes the oxidative
decarboxylation of malate to pyruvate, with a concomitant
production of reduced nicotinamide adenine dinucleotide
phosphate (NADPH), sustaining the redox homeostasis in
PDAC cells. This noncanonic glutamine metabolic pathway is
dispensable in normal cells, but it has the potential to serve as
a promising therapeutic target in PDAC.
Sirtuins (SIRT1–SIRT7) are a class of evolutionarily
conserved nicotinamide adenine dinucleotide (NADþ)–
dependent enzymes that possess deacetylase, desuccinylase,
deglutarylase, and demalonylase activity.6,7 Sirtuins have
been implicated in cancer progression due to their roles in
regulating cancer cell metabolism, tumor microenviron-
ment, and genome stability.8 Among the 7 mammalian sir-
tuins, SIRT5 has been shown to be located in both the
mitochondria and the cytosol.9–11 Given the pleiotropic role
of SIRT5 in regulating cancer cell metabolism, it potentially
can act as a tumor suppressor, or in contrast as an onco-
gene, in different cancer types and microenvironments by
mediating the post-translational modification of its target
substrates.12–19 Yet, the function of SIRT5 in the initiation
and progression of PDAC remains obscure.
The present study revealed SIRT5 to be down-regulated
in both human PDAC tissues and murine pancreatic tumors.
Furthermore, we found SIRT5 deletion to accelerate tumor
growth and to correlate with poor survival in both patients
with PDAC and genetically engineered mouse models. By
integrating mass spectrometry–based metabolomics and
proteomics with biochemical assays, GOT1 was identified as
the critical target substrate in SIRT5-regulated PDAC pro-
gression. Mechanistically, SIRT5 deletion enhanced theenzyme activity of GOT1 by facilitating GOT1 acetylation.
Importantly, SIRT5 activation with a novel small-molecule
activator MC3138 inhibited proliferation in SIRT5-low
PDAC cell lines and organoids. Furthermore, SIRT5 activa-
tion decreased nucleotide levels and facilitated synergy with
gemcitabine in human PDAC organoids and patient-derived
xenografts (PDX). Thus, the present study demonstrates
SIRT5 activation, in combination with gemcitabine, as a
potential therapeutic strategy in PDAC.Materials and Methods
Cell Culture
Human PDAC cell lines Capan1, Capan2, AsPC1, PANC-1,
CFPAC-1, SW1990, and MIAPaCa-2, and HEK 293T were ob-
tained from the American type culture collection (ATCC,
Figure 1. SIRT5 down-regulation in PDAC correlates with disease progression, poor survival outcomes, and enhanced tumor
cell growth. (A) SIRT5 mRNA levels in pancreatic cancer tissues and the paired adjacent normal tissues (39 pairs) from GEO
database. (B–D) Sirt5 mRNA (B) and protein (C–D) levels in 25-week-old Cre control and KPC pancreatic cancer tissues. (E–F)
Immunohistochemistry (IHC) staining and quantification for SIRT5 expression in adjacent normal tissues, low-grade and high-
grade PanINs, and pancreatic tumors. Scale bar 100 mm. (G) Representative IHC staining for SIRT5 expression in pancreatic
cancer tissue microarrays. Scale bar 500 mm. (H–I) Survival analysis of patients with pancreatic cancer categorized by low- and
high-SIRT5 expression. (J–K) Representative images and cell viability for control and SIRT5-knockdown organoids cultured for
7 days. Scale bar 1000 mm. (L–N) Representative image, tumor volume (mean ± SE) and tumor weight of control and SIRT5-
knockdown tumors. (O–P) Ki67 staining and quantitation in control and SIRT5-knockdown tumors. Scale bar 100 mm. For all
in vitro studies, n  3. The data are represented as mean ± standard deviation (SD). Paired Student t test (A, B, D), 1-way
analysis of variance (ANOVA) with Bonferroni test (K, N, P) or Tukey test (F), 2-way ANOVA with Bonferroni test (M), log-
rank test (H–I), *P < .05, **P < .01, and ***P < .001.






November 2021 SIRT5 Inhibits Pancreatic Cancer Progression 1587Rockville, MD). The T3M4, S2-007, HPAF-II, Patu8902, Colo 357
(FG), and S2-013 cell lines were provided by Dr Michael A.
Hollingsworth (Eppley Institute, University of Nebraska Medi-
cal Center [UNMC], Omaha, NE). The murine PDAC cell lines
KPC1245 derived from KrasG12D/þ, p53R172H/þ, Pdx1-Cretg/þ
(KPC) mice were provided by Dr David Tuveson (Cold SpringFigure 2. Sirt5 deficiency accelerates acinar-to-ductal metaplas
Cre; KC: KrasG12D, Pdx1-Cre; KCShet: KrasG12D, Pdx1-Cre, Sirt5
investigating the function of Sirt5 in KrasG12D-driven pancreatic tu
KCShet (n ¼ 9), and KCS (n ¼ 10) mice were euthanized at day
pancreatic tissue from caerulein-injected KC, KCShet, and KCS m
or 500 mm (Alcian blue/eosin staining). (D) The percentage of to
caerulein-treated mice. (E) Histopathologic analysis of pancreat
CK19/Amylase, and Alcian blue/eosin staining of pancreatic tissue
and KCS mice. (G) Percentage of PanIN lesions over the whole p
(n ¼ 5), and KCS mice (n ¼ 6). (H and K) Histopathologic analysis
mice tissue slides. (J) Percentage of PanIN lesion area over the
KCShet (n¼ 6), and KCS mice (n¼ 6). The data are represented as
panels, *P < .05, **P < .01, and ***P < .001.Harbor Laboratory; CSHL). Mouse PDAC cell lines KPC7460,
KPC7472, and KPCS8508, KPCS8009were derived fromKPC and
KPCS mice, respectively. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin and incubated at
37C in a 5% CO2-humidified incubator. The cells wereia, PanIN formation, and pancreatic tumorigenesis. Cre: Pdx1-
fl/þ; KCS: KrasG12D, Pdx1-Cre, Sirt5fl/fl. (A) Genetic strategy for
morigenesis. (B) Intraperitoneally caerulein-injected KC (n ¼ 9),
21. (C) H&E, CK19/Amylase, and Alcian blue/eosin staining of
ice. Scale bars 2000 mm (H&E), 100 mm (immunofluorescence),
tal PanIN area over the whole pancreatic tissue section from
ic tissue sections from caerulein-treated mice. (F and I) H&E,
sections from 4-month-old (F) and 8-month-old (I) KC, KCShet,
ancreatic tissue section from 4-month-old KC (n ¼ 5), KCShet
of 4-month-old (H) and 8-month-old (K) KC, KCShet, and KCS
whole pancreatic tissue section from 8-month-old KC (n ¼ 6),






















PANCREASauthenticated using Short Tandem Repeat (STR) profiling and
tested for mycoplasma contamination using a polymerase chain
reaction (PCR)-based Mycoplasma Detection Kit.
Human Studies
The UNMC Tissue Bank provided the pancreatic cancer
tissues used for PanIN and tumor progression studies, and PDX
models. The UNMC Institutional Review Board Committee
approved the studies related to the use of human samples
for IHC in pancreatic intraepithelial neoplasia (PanIN) lesions.
The UNMC Institutional Review Board Committee also approved
the informed consent waiver. The pancreatic cancer tissue
microarrayused for survival analysiswasobtained fromShanghai
Outdo Biotech (Shanghai, China).
Mouse Strain Generation
The conditional LSL-KrasG12D, Pdx1-Cre,20 and LSL-
Tp53R172H 21 stains were purchased from the National Cancer
Institute. Floxed Sirt5 (Sirt5fl/fl) mice were provided by Dr
Johan Auwerx.22 These mice strains were interbred to produce
the following experimental cohorts: Pdx1-Cre, Sirt5fl/fl (CS);Pdx1-Cre, LSL-KrasG12D (KC); Pdx1-Cre, LSL-KrasG12D, Sirt5fl/fl
(KCS); Pdx1-Cre, LSL-KrasG12D, LSL-Tp53R172H (KPC); and Pdx1-
Cre, LSL-KrasG12D, LSL-Tp53R172H, Sirt5fl/fl (KPCS). For Sirt5
loss-of-function studies, wild-type, Sirt5fl/fl, or Pdx1-Cre litter-
mates were used as controls. These experiment cohort strains
were genotyped using PCR amplification methods. PCR primers
used in genotyping are listed in Supplementary Table 4. For
caerulein-induced pancreatitis, 7-week-old mice of indicated
genotypes were intraperitoneally injected with caerulein (50
mg/kg) for 2 consecutive days every hour for 6 hours each day.
Additional methods are provided in the Supplementary
Material.Results
SIRT5 Down-Regulation Correlates With Disease
Progression, Adverse Patient Outcomes, and
Increased Tumor Cell Growth
The sirtuin family of proteins represents an important
node in the regulation of cellular transcriptional response
when presented with systemic metabolic cues or metabolic/





















PANCREASnutritional changes.23 To investigate whether sirtuins are
dysregulated in PDAC, the present study evaluated the
messenger RNA (mRNA) expression of all the 7 sirtuins in
matched human normal and PDAC tissues from the GEO
database (GDS4103). Results showed that expression levels
of SIRT3, SIRT5, and SIRT6 were significantly decreased
in PDAC tissues, whereas expression levels of SIRT1 and
SIRT7 were remarkably increased in PDAC (Figure 1A,
Supplementary Figure 1A–F). Among the dysregulated sir-
tuins, SIRT5 remains the only sirtuin that has not been
investigated for its role in PDAC. To corroborate the expres-
sion data from GEO, the public database Oncomine was
queriedand that further showedSIRT5expression tobedown-
regulated in PDAC tissues (Supplementary Figure 1G–H).
To establish whether SIRT5 plays a causative role in the
pathogenesis of PDAC, we used the autochthonous LSL-
KrasG12D; LSL-Trp53R172H; Pdx1-Cre (KPC) mouse model and
observed that Sirt5 mRNA and protein levels were signifi-
cantly decreased in KPC pancreatic cancer tissues compared
with the age-matched normal pancreas tissues (Figure 1B–D).
A decrease in SIRT5 expression was noted during the pro-
gression from adjacent normal tissues to PanIN and PDAC in
KPC mouse models (Supplementary Figure 1I–J) and human
samples (Figure 1E–F). Furthermore, low-SIRT5 expression
correlated with tumor recurrence in human patients
(Supplementary Table 1). Low expression of SIRT5 was asso-
ciated with decreased survival of patients with PDAC
(Figure 1G–I). Moreover, low-SIRT5 expression independently
correlated with high mortality risk in patients with PDAC
(Supplementary Figure 1E and Supplementary Tables 1–3).
To examine the effect of SIRT5 on PDAC aggressiveness,
SIRT5 expression was evaluated in 13 PDAC cell lines
(Supplementary Figure 1L). Cells with relatively high expres-
sion of SIRT5 (ie, T3M4, Capan2, PANC1, and S2-007) were
used to generate stable SIRT5 knockdowns, whereas those
with low SIRT5 (ie, S2-013 and Capan1) were chosen to
generate SIRT5-overexpressing cell lines. The efficiency of
SIRT5 knockdown and overexpression was verified using
quantitative PCR and immunoblotting (Supplementary
Figure 1M–Q). SIRT5 knockdown enhanced PDAC cell prolif-
eration, colony formation, and sphere formation
(Supplementary Figure 2A–L). Conversely, SIRT5 over-
expression inhibited PDAC cell growth, whereas the catalyti-
cally inactivemutant SIRT5-H158Y11 did not exhibit significant
inhibitory effects on PDAC cell growth (Supplementary
Figure 2M–P). The expression levels of SIRT5 were also
investigated in a panel of 6 human PDAC tumor-derived
organoid lines, and SIRT5 expression was knocked down in
the PA901 and PA717 organoids with high endogenous SIRT5=
Figure 3.Genomic ablation of Sirt5 promotes PDAC progression
in KrasG12D and Trp53R172H-driven pancreatic tumorigenesis. (B
KPC and KPCS mice. (C) Representative H&E-stained image
KPCShet (n ¼ 4), and KPCS (n ¼ 5) mice at 6, 10, and 15 weeks. S
area over the whole pancreatic tissue sections from KPC, KPCS
analysis of pancreatic tissues from KPC, KPCShet, and KPCS mi
KPCS cohorts at the indicated age. (G–H) Ki67 staining and quan
KPCS mice. Scale bars 100 mm. (I) Kaplan-Meier survival analy
data are represented as mean ± SD. One-way ANOVA with Tukelevels (Supplementary Figure 1R–S). Knockdown of SIRT5 also
increased human PDAC organoid growth (Figure 1J–K).
Moreover, SIRT5 knockdown accelerated T3M4 tumor growth
upon orthotopic implantation (Figure 1L–P).Genetic Ablation of Sirt5 Promotes Pancreatic
Tumorigenesis in Cooperation With Oncogenic
Mutations
To determine the role of SIRT5 in PDAC pathogenesis,
genetically engineered mice were generated that carried
pancreas-specific ablation of Sirt5, along with oncogenic
mutations in Kras alone or Kras and Trp53. Pdx1-Cre;
Sirt5fl/fl (CS) were generated by crossing Pdx1-Cre mice
with Sirt5fl/fl mice (Supplementary Figure 3A–B). As con-
trols, histologic analysis of pancreata isolated from CS and
Pdx1-Cre mice did not show any apparent abnormalities
(Supplementary Figure 3C–D). Furthermore, there was no
significant difference in the body weight changes between
these 2 groups (Supplementary Figure 3E). KrasG12D; Sirt5fl/fl
mice were crossed with Pdx1-Cre; Sirt5fl/þ mice to generate
mice with mutant Kras and heterozygous/homozygous Sirt5
loss, ie, Pdx1-Cre; KrasG12D; Sirt5fl/þ; (KCShet) and Pdx1-Cre;
KrasG12D; Sirt5fl/fl (KCS), respectively (Supplementary
Figure 3A–B and Figure 2A). The cholecystokinin analog
caerulein is a widely used drug to induce pancreatitis.24
Wild type, Pdx1-Cre, and CS mice exhibited expected over-
all nontransformed pancreatic histology 21 days post–
caerulein injection (Supplementary Figure 4A–B).
Conversely, KCS mice had a larger neoplastic area, increased
acinar cell loss (decreased amylase positivity and increased
CK19 positivity), and more high-grade PanIN lesions than the
Pdx1-Cre; KrasG12D (KC) and KCShet mice (Figure 2B–E).
SIRT5 IHC staining of pancreatic tissue from KCS mice
confirmed the efficient deletion of Sirt5 (Supplementary
Figure 4C). Lesions from the KCS mice displayed a signifi-
cantly enhanced cell proliferation index, as indicated by
increased Ki67-staining (Supplementary Figure 4C–D). Thus,
Sirt5 deletion accelerates KrasG12D-triggered pancreatic
tumorigenesis in the context of a caerulein-induced pancre-
atitis model.
Next, the role of Sirt5 in KrasG12D-triggered pancreatic
tumorigenesis was examined in the absence of caerulein.
The pancreata from 4-month-old KCS mice exhibited
significantly larger neoplastic areas as well as higher-grade
PanIN lesions compared with age-matched KC and KCShet
mice (Figure 2F–H). Ki67 staining results showed that the
PanIN ductal cells from KCS mice exhibited an enhanced
proliferative index (Supplementary Figure 4E–F). To. (A) Genetic strategy for investigating the function of the Sirt5
) Representative images of pancreatic tumors in 15-week-old
s of the pancreatic tissue from age-matched KPC (n ¼ 5),
cale bars 2000 mm. (D) Percentage of PanIN and PDAC lesion
het, and KPCS mice at the indicated age. (E) Histopathologic
ce at indicated age. (F) Tumor incidence in KPC, KPCShet, and
tification in pancreatic tumor tissues from KPC, KPCShet, and
sis of the KPC, KPCShet, and KPCS mice (log-rank test). The
y test for panels D and H, *P < .05, **P < .01, and ***P < .001.





















PANCREASidentify the role of Sirt5 at a later stage of KrasG12D-triggered
pancreatic tumorigenesis, pancreatic tissues were collected
from 8-month-old KC, KCShet, and KCS mice. All KCS mice
obtained numerous PanIN lesions at the age of 8 months,
and 2 of 6 KCS mice developed PDAC (Figure 2I–K). The
area, grade, and proliferative potential of PanIN lesions in
KC as well as KCShet mice were significantly lower than the
age-matched KCS mice (Figure 2I–K, Supplementary
Figure 4G–H). These data indicate Sirt5 loss facilitates the
oncogenic KrasG12D-driven initiation of pancreatic tumori-
genesis in the absence of caerulein.
To further examine the effect of Sirt5 deficiency on
pancreatic cancer progression and survival, KPC (Pdx1-Cre;
KrasG12D; Trp53R172H) mice with heterozygous/homozygous
Sirt5 loss (Pdx1-Cre; KrasG12D; Trp53R172H; Sirt5fl/þ, KPCShet
and Pdx1-Cre; KrasG12D; Trp53R172H; Sirt5fl/fl, KPCS) were
generated (Supplementary Figure 3A–B and Figure 3A).
KPCS mice at 15 weeks of age developed large intraperito-
neal pancreatic tumor masses, whereas the corresponding
age-matched KPC mice had only small pancreatic tumor
nodules (Figure 3B). Age-matched KPC and KPCS mice were
assessed at different time points to monitor the pancreatic
tumorigenesis (Figure 3C). At 6 weeks, KPCS mice had a
significantly increased percentage of neoplastic area, and
more than half of the KPCS mice exhibited high-grade PanIN,
which was significantly faster than the age-matched KPC
and KPCShet mice (Figure 3C–E). Complete scans of
pancreatic tissue sections indicated that pancreatic tumors
developed in KPCS mice as early as 10 weeks (40%).
Moreover, 5 of 6 15-week-old KPCS mice developed
pancreatic cancer (Figure 3F). Furthermore, Ki67 staining
results demonstrated Sirt5 deletion significantly promoted
pancreatic cancer cell proliferation (Figure 3G–H). Because
Sirt5 deletion in mice with the KPC background accelerated
pancreatic cancer progression, KPC, KPCShet, and KPCS mice
were then used to investigate the impact of Sirt5 loss on
survival. The KPCS mice had a dramatically shortened me-
dian survival time at 116 days, whereas the median survival
times of KPC and KPCShet mice were 173 days and 148.5
days, respectively (Figure 3I). Therefore, Sirt5 deletion, in
cooperation with Kras and Tp53 mutations, accelerates
pancreatic cancer progression and shortens the survival
time of the spontaneous PDAC progression mouse model.SIRT5 Modulates Pancreatic Cancer Cell Growth
by Suppressing Glutamine and Glutathione
Metabolism
Previous studies have demonstrated that SIRT5 regu-
lated tumorigenesis of multiple cancer types by mediating=
Figure 4. SIRT5 suppresses glutamine and glutathione metaboli
component analysis of metabolic profiles from control and SIRT
of significantly dysregulated metabolites in control and SIRT5
glutamine and glutathione metabolism from control and SIRT5
pyrimidine metabolism from control and SIRT5-knockdown cel
down cells. (J–K) Growth curves of control and SIRT5-knockdow
(L–M) Colony formation assays for control and SIRT5-knockdo
in vitro studies, N  3. The data are represented as mean ± SD.
with Bonferroni test (J–K), *P < .05, **P < .01, and ***P < .001their metabolic reprogramming.12–16 As such, the present
study next investigated whether SIRT5 could regulate PDAC
metabolism. liquid chromatography-coupled tandem-mass
spectrometry (LC-MS/MS)-based metabolite profiles
revealed distinct metabolic alterations between control and
SIRT5-knockdown PDAC cells (Figure 4A–B, Supplementary
Figure 5). Moreover, metabolite set enrichment analysis
indicated that SIRT5 knockdown led to significant changes
in metabolites involved in glutathione metabolism, gluta-
mine metabolism, pyrimidine metabolism, and the tricar-
boxylic acid cycle (Figure 4C–D). SIRT5-knockdown
significantly increased the relative abundance of glutamine
metabolism intermediates (ie, malate, fumarate, and
citrate), glutathione metabolism pathway metabolites
(ie, reduced glutathione (GSH) and NADPH), and the py-
rimidine metabolism intermediates (ie, deoxycytidine
monophosphate [dCMP], cytidine triphosphate [CTP],
deoxythymidine triphosphate [dTTP], deoxyuridine mono-
phosphate [dUMP], uridine triphosphate [UTP]) (Figure 4E–
H, Supplementary Figure 5A–B). SIRT5-knockdown also led
to increased reduction potential as noted by increased
reduced glutathione/oxidized glutathione ratio (GSH/GSSG)
and NADPH/nicotinamide adenine dinucleotide phosphate
(NADP) ratios (Figure 4E–F). Furthermore, the glutamine
uptake was measured in control and SIRT5-knockdown
PDAC cells. These assays revealed the uptake of glutamine
remarkably increased in SIRT5-knockdown cells (Figure 4I).
Interestingly, the differences in cell growth rates between
the control and SIRT5-knockdown PDAC cells were much
greater under the low-glucose (1.25 mmol/L; 5%) condi-
tions than those in normal culture conditions (Figure 4J–M).
These data suggest SIRT5 loss increases glutamine use to
maintain redox balance and support PDAC cell growth even
under glucose-limited conditions.SIRT5 Induces Dysregulated Glutamine and
Glutathione Metabolism via GOT1
Next, we investigated the mechanistic basis of SIRT5-
mediated dysregulation of glutamine and glutathione
metabolism in PDAC. KRAS-mutated PDAC cells rely on
noncanonic glutamine metabolism (Figure 5A).5 There were
no significant differences in mRNA or protein levels of
noncanonic glutamine metabolic pathway enzymes upon
SIRT5 knockdown (Supplementary Figure 6A–C). As such,
the present study measured the enzymatic activities of en-
zymes including glutaminase (GLS), GLUD1, and GOT from
control and SIRT5-knockdown PDAC cell extracts. Interest-
ingly, suppression of SIRT5 in PDAC cells significantly pro-
moted the enzyme activity of GOT, but not GLS or GLUD1sm, and regulates cellular redox homeostasis. (A–B). Principal
5-knockdown cells (N ¼ 5). (C–D) Metabolic pathway analysis
-knockdown cells. (E–F) Significantly different metabolites in
-knockdown cells. (G–H) Significantly different metabolites in
ls. (I) Relative glutamine uptake in control and SIRT5-knock-
n cells cultured under low-glucose conditions (1.25 mmol/L).
wn cells under low-glucose conditions (1.25 mmol/L). For all
One-way ANOVA with Bonferroni test (E–I, M), 2-way ANOVA
.





















PANCREAS(Figure 5B and Supplementary Figure 6D–E). Next, the
control and SIRT5-knockdown PDAC cells were treated with
inhibitors of glutamine pathway metabolic enzymes to
examine their selective responsiveness to these inhibitors
(Supplementary Figure 6F). Results showed SIRT5-knock-
down PDAC cells were more sensitive to GOT-inhibitor
aminooxyacetate (AOA) than control cells (Figure 5C–D),
but there was no significant difference between control and
SIRT5-knockdown cells when treated with GLS-inhibitor
BPTES and GLUD1-inhibitor EGCG (Supplementary
Figure 6G–J). Moreover, orthotopic implantation studies
demonstrated SIRT5-knockdown T3M4 cells were more
vulnerable to AOA treatment (Figure 5E–G, Supplementary
Figure 6K–L). These data indicate SIRT5 inhibits gluta-
mine/glutathione metabolism primarily by suppressing the
enzyme activity of GOT.
To further identify which GOT isoform (GOT1 or GOT2)
is the primary target of SIRT5, GOT1 and GOT2 were
knocked down in both control and SIRT5-knockdown
PDAC cells (Supplementary Figure 6M–P). GOT1 silencing
abolished SIRT5-knockdown-induced PDAC cell growth
(Figure 5H–I), whereas knockdown of GOT2 did not
significantly affect cell growth in all of the SIRT5-knock-
down cells under low-glucose (1.25 mmol/L) conditions
(Supplementary Figure 6Q–R). These data preliminarily
indicate that GOT1 plays a major role in SIRT5-loss–
mediated cell growth. To confirm the regulation of GOT1
by SIRT5, metabolites from control, GOT1-knockdown,
SIRT5-knockdown, and SIRT5/GOT1-double-knockdown
cells were subjected to LC-MS/MS-based metabolomic
analysis. SIRT5-knockdown cells demonstrated signifi-
cantly increased ratios of reduced-glutathione to oxidized-
glutathione (GSH/GSSG) and cellular reduced nicotinamide
adenine dinucleotide phosphate/oxidized nicotinamide
adenine dinucleotide phosphate (NADPH/NADP), which
was abolished by GOT1 knockdown (Figure 5J–K). GOT1
catalyzes the conversion reactions of 2-ketoglutarate and
aspartate into glutamate and oxaloacetate. The metab-
olomics data indicated SIRT5 knockdown increased the
abundance of the GOT1 downstream intermediates (ie,
malate, fumarate). Contrastingly, SIRT5-loss–induced in-
crease in malate and fumarate levels was abolished by the
GOT1 knockdown, with a concomitant increase in the=
Figure 5. SIRT5 inhibits glutamine and glutathione metabolism
illustration of the Kras-regulated glutamine and glutathione meta
activity in control and SIRT5-knockdown cells. (C–D) Relative su
inhibitor AOA. Data are normalized to the respective untreated g
shSIRT5 cells in vivo. Tumor growth rates at indicated time poin
necropsy (G). (H–I) Cell growth of control and SIRT5-knockdow
(shRNA) under low-glucose conditions (1.25 mmol/L). Exper
transfected with GOT1 or GOT2 shRNA were set up together
adenine dinucleotide phosphate/oxidized nicotinamide adenin
GSSG ratio (K) in control, GOT1-knockdown, SIRT5-knockdow
glutathione; GSSH, oxidized glutathione. (L) Relative intracellula
ROS-insensitive carboxy-DCFDA (CDCFDA) dye was used as
glutamine carbon incorporation into downstream metabolites i
GOT1-double-knockdown T3M4 cells. Asp, aspartate; Glu, gluta
as mean ± SD. One-way ANOVA with Bonferroni test (B) or Tuk
test (M), *P < .05, **P < .01, and ***P < .001.levels of the precursor metabolite 2-ketoglutarate
(Supplementary Figure 6S-T). As the reducing equivalent
NADPH and GSH are important for cellular redox homeo-
stasis, SIRT5 knockdown was posited to increase the
generation of NADPH and GSH to maintain redox balance
and promote cell proliferation in PDAC cells. As expected,
GOT1 silencing abrogated a SIRT5-knockdown–mediated
decrease of the intracellular reactive oxygen species (ROS)
levels (Figure 5L). Furthermore, [U-13C5] glutamine-based
kinetic flux analysis demonstrated SIRT5 knockdown
significantly increased levels of 13C-labeled malate and
fumarate; these increased levels were abolished by GOT1
knockdown (Figure 5M). Taken together, these findings
indicate that SIRT5 inhibits glutamine/glutathione meta-
bolism and regulates cellular redox homeostasis by
attenuating the enzymatic activity of GOT1.SIRT5 Inhibits GOT1 Enzymatic Activity by
Catalyzing its Lysine Deacetylation
We then investigated the mechanistic basis of SIRT5-
mediated modulation of GOT1 activity. Considering SIRT5
has been found to regulate metabolic enzymatic activity by
altering the post-translational modifications in
enzymes,11,25–28 the present study examined whether SIRT5
potentially catalyzes lysine post-translational modifications
in GOT1. Interestingly, the lysine acetylation level of GOT1
decreased upon SIRT5 overexpression in PDAC cells,
whereas the lysine glutarylation, succinylation, or malony-
lation levels of GOT1 remained unaltered or undetectable
(Figure 6A). In contrast, SIRT5-knockdown significantly
increased the acetylation level of both exogenous GOT1
(Figure 6B) and endogenous GOT1 (Supplementary
Figure 7A). Moreover, the catalytically inactive mutant
SIRT5-H158Y11 failed to induce the deacetylation of GOT1
protein compared with the wild-type SIRT5 (Figure 6C). To
further identify the SIRT5-dependent deacetylation sites on
GOT1, GOT1 protein was purified from the control and
SIRT5-knockdown T3M4 cells, and post-translational modi-
fications were assessed using mass spectrometry. As shown
in Figure 6D and Supplementary Figure 7B–G, 3 acetylation
sites (lysine 276, lysine 290, and lysine 369) were found in
both control and SIRT5-knockdown cells. In addition, aby decreasing GOT1 enzyme activity. (A) The schematic
bolism in mutant Kras-driven PDAC. (B) Relative GOT enzyme
rvival of control and SIRT5-knockdown cells treated with GOT
roup. (E–G) Effect of AOA treatment on T3M4 shScramble and
ts (E). Tumor volume (F) and tumor weight in each group upon
n cells transfected with control or GOT1 short hairpin RNA
iments for scrambled control and SIRT5-knockdown cells
with common controls. (J–K) Relative reduced nicotinamide
e dinucleotide phosphate (NADPH/NADP) ratio (J) or GSH/
n, and SIRT5/GOT1-double-knockdown cells. GSH, reduced
r reactive oxygen species (ROS) levels in the indicated cells.
a negative control. (M) Kinetic flux analysis of 13C-labeled
n control, GOT1-knockdown, SIRT5-knockdown, and SIRT5/
mate. For all in vitro studies, N  3. The data are represented
ey test (F–L), 2-way ANOVA with Tukey test (E) or Bonferroni





















PANCREAScomparison of the lysine acetylation intensities of GOT1
between control and SIRT5-knockdown cells indicated
lysine 369 as the major lysine target residue that SIRT5
deacetylates (Figure 6D).
To identify if SIRT5-catalyzed post-translational modifi-
cations of GOT1 regulated GOT1 activity, we performed site-
directed mutagenesis. The lysine to arginine (ie, K-to-R)
mutation preserves the positive charge but cannot be acet-
ylated, and is frequently used as a deacylated lysine
mimetic.29 Hence, 3 mutant HA-tagged GOT1 plasmids were
generated, in which the lysine 276, lysine 290, or lysine 369
residues were substituted with arginine (R). The wild-type
GOT1 plasmid, GOT1-K276R, GOT1-K290R, and GOT1-K369R
mutant plasmids were transfected into control and SIRT5-
knockdown T3M4 cells. Immunoblots of the purified GOT1
protein from cells expressing wild-type GOT1, GOT1-K276R,
GOT1-K290R, and GOT1-K369R mutants were used to
detect the acetylation levels of GOT1. The K369R mutation
resulted in a significant decrease in the acetylation level of
GOT1 (Figure 6E–F). Furthermore, SIRT5-knockdown
significantly increased the lysine acetylation levels of wild-
type GOT1, GOT1-K276R, and GOT1-K290R mutants, but
not the GOT1-K369R mutant (Figure 6E–F). These data
indicate lysine 369 in GOT1 protein is the primary
deacetylation target of SIRT5. To further evaluate the
function of GOT1-K369 acetylation under SIRT5-knockdown
conditions, first the CRISPR/Cas9 technique was used to
generate GOT1-knockout/SIRT5-knockdown cells. The
above GOT1-knockout/SIRT5-knockdown cells were then
engineered to re-express vector, wild-type GOT1, or GOT1-
K369R mutant plasmids (Figure 6G–H). GOT1 knockout
abolished SIRT5-knockdown–mediated increase of GOT
enzymatic activity, while re-expressing wild-type GOT1, but
not GOT1-K369R, restored this activity (Figure 6I). Thus,
K369 deacetylation by SIRT5 is primarily responsible for
SIRT5-mediated abrogation of GOT activity in PDAC cells.
GOT1 knockout inhibited the effects of SIRT5-knock-
down on cell growth, whereas re-expression of wild-type
GOT1 rescuedcell growth. However, re-expression
of GOT1-K369R failed to restore cell growth in=
Figure 6. SIRT5 inhibits GOT1 enzymatic activity by catalyzing it
succinylation, and malonylation levels of GOT1 protein immun
cells. Inputs are shown below. (B) The lysine acetylation level o
knockdown T3M4/Capan2 cells. Inputs are shown below. (C) Th
from PDAC cells transfected with vector, SIRT5, and mutant SI
GOT1 protein immunoprecipitated from control and SIRT5-knoc
schematic representation of 3 acetylation sites identified in GOT
acetylation sites in GOT1. (E–F) Wild-type GOT1, GOT1-K276
transfected into control and SIRT5-knockdown T3M4 cells. The
from above cells; inputs are shown below (E). The quantification
(F). (G–H) The immunoblotting of SIRT5 and GOT1 levels in s
knockdown/GOT1-knockout cells transfected with vector, GOT
scrambled control cells, SIRT5-knockdown cells, and SIRT5-kno
or GOT1-K369R plasmids. (J–K) Cell growth analysis of scr
knockdown/GOT1-knockout cells transfected with vector, GO
conditions (1.25 mmol/L). (L) Kinetic flux analysis of 13C-labele
lites in scrambled control cells, SIRT5-knockdown cells, or SIR
wild-type GOT1, or GOT1-K369R plasmids. For all in vitro stud
t-test (D, F), 1-way ANOVA with Tukey test (I–K), 2-way ANOVAGOT1-knockout/SIRT5-knockdown PDAC cells under low-
glucose (1.25 mmol/L) conditions (Figure 6J–K). Consis-
tently, the [U-13C5] glutamine-based kinetic flux analysis
indicated GOT1 knockout abolished the increased 13C-
labeled malate and fumarate levels in SIRT5-knockdown
cells. Moreover, re-expressing wild-type GOT1 could restore
the 13C-labeled malate and fumarate levels in GOT1-
knockout/SIRT5-knockdown cells, whereas expressing
GOT1-K369R was unable to rescue this phenomenon
(Figure 6L). Taken together, these results strongly indicate
that SIRT5 suppresses GOT1 enzymatic activity by deace-
tylating GOT1 at lysine 369, which leads to the inhibition of
tumor cell growth.Targeting PDAC With Small-Molecule SIRT5-
Activator MC3138 Improves Therapeutic
Efficiency
Given the important role of SIRT5 in the development of
PDAC, it has the potential to serve as a promising drug
target. A small-molecule SIRT5 activator, a 1,4-
dihydropyridine, termed MC3138, was developed
(Figure 7A) and tested for potential effects on human PDAC
cell lines, organoids, and PDX tumors. The biochemical
enzymatic assay results indicated that MC3138 exhibited a
selective activation of SIRT5 compared with the selective
SIRT1 activator SRT2104 and SIRT3 activator Honokiol
(Supplementary Figure 8A–C). Moreover, treatment with
MC3138 mimicked the deacetylation effect mediated by
SIRT5 overexpression (Supplementary Figure 8D). MC3138
treatment decreased lysine acetylation of the GOT1 protein
and inhibited its enzymatic activity (Figure 7B–C). The cell
viability assay showed MC3138 reduced PDAC cell viability,
with half maximal inhibitory concentration (IC50) values
ranging from 25.4 mmol/L–236.9 mmol/L (Figure 7D and
Supplementary Figure 8E–F). To validate whether the
inhibitory effect of MC3138 was associated with activation
of SIRT5, a correlation analysis between the IC50 of
MC3138 and SIRT5 protein levels was performed. The IC50
value of MC3138 positively correlated with SIRT5 proteins lysine deacetylation. (A) The lysine acetylation, glutarylation,
oprecipitated from control and SIRT5-overexpressing PDAC
f GOT1 protein immunoprecipitated from control and SIRT5-
e lysine acetylation level of GOT1 protein immunoprecipitated
RT5-H158Y plasmid. Inputs are shown below. (D) Exogenous
kdown T3M4 cells was subjected to proteomic analysis. Top,
1; bottom, the mass spectrometric signal intensity of indicated
R, GOT1-K290R, and GOT1-K369R mutant plasmids were
lysine acetylation levels of GOT1 protein immunoprecipitated
of relative lysine acetylation level of indicated acetylation sites
crambled control cells, SIRT5-knockdown cells, and SIRT5-
1, or GOT1-K369R plasmid. (I) The GOT enzyme activity in
ckdown/GOT1-knockout cells transfected with vector, GOT1,
ambled control cells, SIRT5-knockdown cells, and SIRT5-
T1, or GOT1-K369R plasmids, cultured under low-glucose
d glutamine carbon incorporation into downstream metabo-
T5-knockdown/GOT1-knockout cells transfected with vector,
ies, N  3. The data are represented as mean ± SD. Student
with Tukey test (L), *P < .05, **P < .01, and ***P < .001.





















PANCREASlevels (Figure 7E). Moreover, MC3138 was tested in mouse
KPC and KPCS cells. Because KPCS cells do not express
SIRT5, these cells were, as expected, resistant to MC3138
treatment (Figure 7F). Conversely, the SIRT1 activator
SRT2104 and SIRT3 activator Honokiol did not exhibit se-
lective growth inhibition between KPC and KPCS cells
(Supplementary Figure 8G–H). Because SIRT5 knockdown
significantly increased the metabolite levels in glutamine,
glutathione, and pyrimidine metabolism pathways
(Figure 4E–H), these metabolites levels were also investi-
gated in PDAC cells treated using MC3138. MC3138 treat-
ment decreased the metabolite levels in these pathways
(Supplementary Figure 8I–L). Our previous studies identi-
fied that the increase of endogenous pyrimidine pools can
diminish the therapeutic efficiency of pyrimidine analog
gemcitabine by molecular competition.30 Next, the combi-
national effect of MC3138 and gemcitabine, a first-line Food
and Drug Administration–approved chemotherapeutic to
treat patients with PDAC, was investigated. A combination of
gemcitabine and MC3138 at different dosages exhibited
synergistic effects in CFPAC-1 and Colo357/FG cells
(Supplementary Figure 8M–P). Likewise, gemcitabine com-
bined with MC3138 was synergistic at different concentra-
tions in human PDAC organoids with low-SIRT5 expression
(Figure 7G–L). The MC3138 pharmacokinetics showed that
the maximum concentration and half-life of MC3138 in
plasma was around 230 mmol/L and 5.059 hours, respec-
tively (Supplementary Figure 8Q). To further investigate the
effect of gemcitabine combined with MC3138 in vivo, PDX
tumors (PA137) were orthotopically implanted in NOD-SCID
mice. The concentration of MC3138 in the MC3138-treated
tumors ranged from around 100–200 mmol/L, with the
average as 143.57 mmol/L, indicating that MC3138 was
efficiently delivered to the tumor tissues (Supplementary
Figure 8R). The combination of gemcitabine and MC3138
significantly decreased tumor size, tumor weight, and tumor
proliferation cell index in mice (Figure 7M–O,
Supplementary Figure 8S–T). In addition, the GOT activity
was significantly decreased in the MC3138-treated tumors
(Supplementary Figure 8U). More importantly, the admin-
istered drug combination was well tolerated in mice because
no significant alterations were observed in body weight and
blood biochemistry indices (Supplementary Figure 8V–W).
Collectively, these data indicate that gemcitabine combined=
Figure 7. SIRT5 activator MC3138 exhibits antitumor effects a
noids, and PDX models. (A) The chemical structure of SIRT5 ac
MC3138. Protein is shown in purple flat ribbon and compound i
GOT1 protein immunoprecipitated from PDAC cells treated wit
Inputs are shown below. (C) The GOT enzyme activity in PDA
(D) IC50 data of 10 wild-type PDAC cell lines treated using MC
level (from Supplementary Figure 1L) and IC50 of MC3138 in PD
knockout KPC cell (KPCS) treated with MC3138. (G–H, J–K)
PA417 (G–H) and PA137 (J–K) treated with indicated concentra
index (CI) of gemcitabine and MC3138 at indicated concentrati
the combination therapy treatment. (M–O) Effect of MC3138
Representative tumor images on necropsy (M). Tumor volum
necropsy (O). Gem, gemcitabine; MC, MC3138. For all in vitro
Student t test (C), 1-way ANOVA with Tukey test (H, K, O), 2
***P < .001.with SIRT5 activator MC3138 can be a potential therapeutic
option for PDAC with low-SIRT5 expression.Discussion
In this work, we established a novel tumor suppressor
function of SIRT5 in PDAC cell lines, organoids, orthotopic
and spontaneous models, and patients. SIRT5 knockdown
increased PDAC cell growth in normal and nutrient-limited
conditions, whereas SIRT5 overexpression diminished
PDAC cell growth. Genetic ablation of Sirt5 in the mouse
spontaneous tumor progression model accelerated acinar-
to-ductal metaplasia, PanIN formation, and pancreatic
tumorigenesis, which results in decreased survival.
Previous studies demonstrate that Kras-mutated PDAC
can reprogram its metabolism to adapt to the harsh
microenvironment.5 However, the molecular regulators
downstream of oncogenic Kras that mediate metabolic ad-
aptations remain poorly characterized. Our present study
shows Sirt5 mRNA and protein levels are decreased in KPC
tumor tissues. In the genetically engineered mouse model
with the oncogenic KrasG12D mutation, Sirt5 ablation accel-
erated PanIN formation and PDAC progression. Hence, Sirt5
loss potentially functions downstream of Kras, and facili-
tates the oncogenic Kras mutation-driven PDAC initiation
and development.
Previous studies reveal oncogenic Kras mutation-driven
PDAC cells use glutamine in a noncanonic way via the GOT2-
GOT1-ME1 pathway.5,31 However, the mechanistic basis of
Kras-mediated induction of the pathway is not fully un-
derstood. Accordingly, our present study shows that SIRT5
can suppress PDAC progression by inhibiting the GOT1-
mediated glutamine/glutathione metabolic pathway via
post-translational modification of GOT1. Notably, SIRT5
knockdown sensitizes PDAC cells to the GOT-inhibitor AOA
both in vitro and in vivo. Although the GOT-inhibitor AOA is
a pan-aminotransferase inhibitor,32,33 SIRT5-knockdown
PDAC cells with significantly higher GOT1 activity were
much more sensitive to AOA treatment both in vitro and
in vivo (Figure 5B–G). Combined with increased glutamine
uptake of SIRT5 knockdown cells, these results indicate
SIRT5-mediated deacetylation of GOT1 as a metabolic
switch that must be inactivated to facilitate Kras-induced
glutamine addiction. Notably, very few studies havend synergism with gemcitabine in human PDAC cells, orga-
tivator MC3138 and an enlarged view of SIRT5 docked with
s depicted via a stick model. (B) The lysine acetylation level of
h dimethyl sulfoxide (DMSO) or 10 mmol/L MC3138 for 24 h.
C cells treated with DMSO or 10 mmol/L MC3138 for 24 h.
3138. (E) Pearson correlation analysis between SIRT5 protein
AC cell lines. (F) Relative cell survival of KPC cell and SIRT5-
Representative images and cell viability of PDAC organoids
tion of gemcitabine and MC3138 for 72 h. (I, L) Combination
ons. “Effect” in the Table refers to the relative cell survival on
in combination with gemcitabine on PDX (PA137) model.
es are represented as mean ± SEM (N). Tumor weight on
studies, N  3. The data are represented as mean ± SD.
-way ANOVA with Tukey test (N), *P < .05, **P < .01, and
















ASreported direct regulation of glutamine metabolism in can-
cer cells via post-translational modifications that provide
nutritional flexibility. Yang et al34 showed that SIRT3
regulated the malate-aspartate shuttle activity by deacety-
lating GOT2 in pancreatic cancer. However, unlike GOT1,
GOT2 knockdown could not abolish SIRT5 knockdown-
induced increased cell growth under low-glucose condi-
tions. Two other SIRT5-mediated post-translational
modifications have been reported to target glutamine
metabolism via SIRT5-mediated desuccinylation of GLS in
breast cancer and deglutarylation of GLUD1 in colorectal
cancer that increased glutamine uptake and metabolism to
support proliferation in other tumor models.13,16
Conversely, we report increased glutamine uptake and
enhanced cell growth in PDAC upon SIRT5 knockdown. Of
note, in a previous study, GLUD1 knockdown failed to
diminish Kras-induced PDAC cell growth; however, GOT1
knockdown significantly inhibited tumor cell growth.5 These
studies are further supported by our findings and lead to
the notion that the mechanistic regulation of glutamine
metabolism is distinct in Kras-driven PDAC tumors as
compared with tumors of other origin and noncancer cells
that are dependent on the canonic glutamine metabolism.
Thus, our study demonstrates the mechanistic regulation of
noncanonic glutamine metabolism via post-translational
modifications in PDAC cells with activating KRAS mutations.
Our current study provides the first evidence in support
of SIRT5 activation as a therapeutic strategy. We developed a
novel first-in-class small-molecule SIRT5 activator, MC3138,
which shows selectivity over SIRT1 and SIRT3. Furthermore,
MC3138 synergized with gemcitabine in human PDAC cell
lines, organoids, and PDX tumors with low-SIRT5 expres-
sion. A SIRT5 loss-mediated increase in pyrimidine nucleo-
tide pools provides a potential mechanistic basis for the
synergistic effect of the combination with gemcitabine. These
results are in line with previous studies demonstrating that
molecular competition with increased endogenous pyrimi-
dine pools can outcompete pyrimidine analog gemcitabine
and impart resistance.30 Of note, the toxicity assays indicated
MC3138 combined with gemcitabine was well tolerated in
mice. These results demonstrate that MC3138 combined
with gemcitabine can be a safe and effective therapeutic
option for PDAC with low-SIRT5 expression.
In conclusion, our study identifies a vital role SIRT5
plays in regulating glutamine/glutathione metabolism dur-
ing the initiation and progression of PDAC. Moreover, our
data indicate a synergistic effect of the small-molecule
SIRT5-activator MC3138 combined with gemcitabine in
human PDAC organoids and PDX models. As such, these
findings shed new light on the potential use of SIRT5 acti-
vation as a novel therapeutic strategy for patients with
PDAC with decreased SIRT5 expression.
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